First Trust Advisors LP Grows Position in LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 998,071 shares of the medical instruments supplier’s stock after purchasing an additional 57,931 shares during the quarter. First Trust Advisors LP’s holdings in LeMaitre Vascular were worth $108,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. M&T Bank Corp boosted its stake in LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock worth $32,283,000 after buying an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. grew its position in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after acquiring an additional 231,157 shares during the last quarter. Bessemer Group Inc. raised its stake in shares of LeMaitre Vascular by 292.3% during the first quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after acquiring an additional 128,033 shares in the last quarter. Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 20.1% in the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after acquiring an additional 105,921 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the transaction, the director owned 3,942 shares in the company, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 54,453 shares of company stock valued at $5,906,174. Insiders own 7.40% of the company’s stock.

LeMaitre Vascular Trading Down 1.3%

Shares of LMAT opened at $97.49 on Friday. LeMaitre Vascular, Inc. has a 1-year low of $79.00 and a 1-year high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average price is $97.04 and its 200-day moving average price is $99.05. The firm has a market capitalization of $2.23 billion, a price-to-earnings ratio of 35.97, a PEG ratio of 2.74 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were issued a $0.25 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $1.00 annualized dividend and a yield of 1.0%. LeMaitre Vascular’s payout ratio is 36.90%.

Analyst Upgrades and Downgrades

LMAT has been the subject of several analyst reports. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday. Wells Fargo & Company lifted their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Citizens Jmp boosted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.